1-(2-甲基-1,3-苯并噻唑-6-基)乙酮 | 20077-92-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 1-(2-甲基-1,3-苯并噻唑-6-基)乙酮
• 英文名称: 2-methylbenzothiazol-5-yl methyl ketone
• 英文别名: 1-(2-methyl-6-benzothiazolyl)ethanone；1-(2-methyl-benzothiazol-6-yl)-ethanone；2-methyl-6-benzothiazolyl methyl ketone；2-Methyl-6-acetyl-benzthiazol；6-Acetyl-2-methyl-benzthiazol；1-(2-Methylbenzo[d]thiazol-6-yl)ethanone；1-(2-methyl-1,3-benzothiazol-6-yl)ethanone
• CAS: 20077-92-3
• 化学式: C₁₀H₉NOS
• 分子量: 191.254
• InChiKey: CCSCEVNEBAYVTC-UHFFFAOYSA-N

物化性质

• 熔点：
  86.5 °C
• 沸点：
  318.5±15.0 °C(Predicted)
• 密度：
  1.241±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  58.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-甲基-1,3-苯并噻唑-6-基)乙酮 在 溴 作用下， 以 溶剂黄146 为溶剂， 反应 1.5h， 生成 2-bromo-1-(2-methyl-benzothiazol-6-yl)-ethanone
  参考文献：
  名称：

  Zubarovskii,V.M.; Khodot,G.P., Journal of general chemistry of the USSR, 1962, vol. 32, p. 1559 - 1564

  摘要：

  DOI：
• 作为产物：
  描述：

  4-乙酰胺基-3-溴苯乙酮 在 tris(dibenzylideneacetone)dipalladium (0) sodium ethanolate 、 N,N-二异丙基乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 为溶剂， 反应 13.0h， 生成 1-(2-甲基-1,3-苯并噻唑-6-基)乙酮
  参考文献：
  名称：

  A Novel Practical Synthesis of Benzothiazoles via Pd-Catalyzed Thiol Cross-Coupling

  摘要：

  A convenient synthesis of substituted benzothiazoles from 2-bromoanilides has been accomplished. The various 2-bromoanilides were reacted with an alkyl thiolate in high yields using a palladium catalyst. The resulting sulfides were easily converted to the corresponding benzothiazoles via the simultaneous generation of thiols and condensation under basic or acidic conditions.

  DOI：

  10.1021/ol7015737

文献信息

• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019243528A1

  公开（公告）日：2019-12-26

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病的用途，例如tau病变，特别是阿尔茨海默病或进行性上行性麻痹; 以及伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩性侧索硬化或额颞叶痴呆。
• Efficient and Economical Access to Substituted Benzothiazoles: Copper-Catalyzed Coupling of 2-Haloanilides with Metal Sulfides and Subsequent Condensation
  作者：Dawei Ma、Siwei Xie、Peng Xue、Xiaojing Zhang、Jinhua Dong、Yongwen Jiang

  DOI：10.1002/anie.200900486

  日期：2009.5.25

  Don′t tell azole: The first metal‐catalyzed direct coupling of metal sulfides with aryl halides and subsequent intramolecular condensation provided substituted benzothiazoles (see scheme). A wide range of functional groups are tolerated under the reaction conditions.

  不要告诉唑：金属硫化物与芳基卤化物的首次金属催化直接偶联，以及随后的分子内缩合提供了取代的苯并噻唑（参见方案）。在反应条件下可耐受多种官能团。
• [EN] TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSÉS MODULATEURS DE TLR2, COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：AXIAL THERAPEUTICS INC

  公开号：WO2021242923A1

  公开（公告）日：2021-12-02

  The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.

  本公开涉及调节Toll样受体（TLR）蛋白活性的化合物，包括激动剂或激活剂、部分激动剂和拮抗剂。特别感兴趣的是调节TLR2活性的化合物，以及使用这些化合物治疗与TLR2通路相关的癌症和其他疾病的方法。
• EPOTHILONE ANALOGUES, THEIR PHARMACEUTICAL COMPOSITIONS, THEIR USE AND THEIR PREPA RATIONS
  申请人：Tang Li

  公开号：US20110112149A1

  公开（公告）日：2011-05-12

  The present invention relates to novel 15-membered thiazole lactone or lactam polyketide compounds, their pharmaceutical compositions, their use and their preparations. The disclosed compounds relate to those of general formula I, their preparations and their use for preparing therapeutical compositions used as cell inhibitors.

  本发明涉及新型的15-成员噻唑内酯或内酰胺多酮化合物，它们的药物组合物，它们的用途和它们的制备。所公开的化合物涉及一般式I的化合物，它们的制备以及它们用于制备作为细胞抑制剂使用的治疗组合物。
• Heteroaryl amines as novel acetylcholinesterase inhibitors
  申请人：——

  公开号：US20020049210A1

  公开（公告）日：2002-04-25

  Compounds of the formula 1 wherein ring A, ring B, ring D, R 2 , R 3 , R 4 , R 5 , R 6 ,R 11 , R 12 , R 13 , E, G, X and P are as defined below. The compounds of formula I are cholinesterase inhibitors and are useful in enhancing memory in patients suffering from dementia and Alzheimer's disease.

  化合物的公式为1，其中环A、环B、环D、R2、R3、R4、R5、R6、R11、R12、R13、E、G、X和P的定义如下。式I的化合物是胆碱酯酶抑制剂，对于患有痴呆症和阿尔茨海默病的患者增强记忆力具有有用的作用。